好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Cerebellar Involvement During Attacks of Aquaporin-4-IgG Positive Neuromyelitis Optica Spectrum Disorder
Autoimmune Neurology
C13 - Neuromyelitis Optica and MOG-antibody Associated Disease Diagnosis and Treatment (11:18 AM-11:25 AM)
P2 - Poster Session 2 (2:45 PM-3:45 PM)
010

To describe clinical and radiological features of cerebellar involvement during and following attacks of aquaporin-4-IgG positive neuromyelitis optica spectrum disorder (AQP4+NMOSD).

Cerebellar attacks are not a core clinical characteristic of 2015 AQP4+NMOSD diagnostic criteria and lack detailed characterization with a paucity of prior studies.

Brain MRI from AQP4+NMOSD patients were screened for cerebellar T2/FLAIR hyperintense lesions. Inclusion criteria were: 1) AQP4+NMOSD; 2) MRI with cerebellar lesion(s) ≤40 days from attack onset. 

From 432 patients, 18 (4%) were included (at onset, 9; at subsequent attack, 9). The median age at onset was 49 years (range, 7-74), 17 (94%) were female and 12 were White. Cerebellar symptoms or signs occurred in 16/18 (89%) and included: gait ataxia, 9 (56%); diplopia, 8 (50%); vertigo, 7 (44%); nystagmus, 6 (38%); dysarthria, 3 (19%), appendicular ataxia, 2 (11%); or other, 2 (11%). Sixteen had concomitant attacks in one or more other regions: brainstem, 13 (area postrema, 5); spinal cord, 4: optic nerve, 2: cerebral, 1. Median EDSS at nadir (available in 9) was 8 (range, 2-9). CSF showed: pleocytosis, 7/13 (54%); positive oligoclonal bands 1/13 (8%). Cerebellar MRI T2-lesions (14 single; 4 multiple; 10 contiguous with brainstem) involved: cerebellar peduncles,14 (78%) (unilateral, 10 [71%]; bilateral, 4 [29%]; inferior, 2 [14%]; middle, 11 [61%]; superior, 6 [33%]); dentate nucleus, 3 (17%); medial cerebellum, 3 (17%); lateral hemispheres, 2 (11%). None had vermis or tonsil lesions. Contrast enhancement was observed in 4/15 (27%). Follow-up imaging (n=12), after a median of 15 months (range:6-49) showed that the lesions persisted in 10 (83%) and resolved in 2 (17%). 

Cerebellar involvement occurs in a minority of AQP4+NMOSD attacks, but is important to recognize as it may be the heralding manifestation and attacks can be severe. Future iterations of the AQP4+NMOSD criteria could incorporate cerebellar attacks.

Authors/Disclosures
Alessandro Dinoto, MD
PRESENTER
The institution of Dr. Dinoto has received research support from Encephalitis International . The institution of Dr. Dinoto has received research support from Autoimmune Encephalitis Alliance.
Laura Cacciaguerra, MD, PhD (Mayo Clinic) Dr. Cacciaguerra has nothing to disclose.
John Chen John Chen has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. John Chen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen.
Karl Krecke Karl Krecke has nothing to disclose.
Dean M. Wingerchuk, MD, FAAN (Mayo Clinic) Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Imcyse. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TTY Biopharm. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Reistone Biopharm. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Meyer Squibb. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AstraZeneca. Dr. Wingerchuk has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Wingerchuk has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abcuro. Dr. Wingerchuk has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Wolters Kluwers.
Samantha Banks, MD (Mayo Clinic) Dr. Banks has nothing to disclose.
Alfonso S. Lopez, MD (Mayo Clinic) Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon. Dr. Lopez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech .
Cristina Valencia Sanchez, MD (Mayo Clinic Arizona) Dr. Valencia Sanchez has a non-compensated relationship as a member of the medical advisory board with The MOG Project that is relevant to AAN interests or activities.
Sean J. Pittock, MD, FAAN (Mayo Clinic Dept of Neurology) Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Arialys Therapeutics. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Arialys. The institution of Dr. Pittock has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. The institution of Dr. Pittock has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. The institution of Dr. Pittock has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from NIH. The institution of Dr. Pittock has received research support from Alexion/AstraZeneka. The institution of Dr. Pittock has received research support from F. Hoffman/LaRoche/Genentech. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received intellectual property interests from a discovery or technology relating to health care. Dr. Pittock has received publishing royalties from a publication relating to health care.
Eoin P. Flanagan, MBBCh, FAAN (Mayo Clinic) The institution of Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Flanagan has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Flanagan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Pharmacy times. The institution of Dr. Flanagan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. The institution of Dr. Flanagan has received research support from Viela Bio. The institution of Dr. Flanagan has received research support from UCB. The institution of Dr. Flanagan has received research support from Roche. Dr. Flanagan has received publishing royalties from a publication relating to health care. Dr. Flanagan has a non-compensated relationship as a Member of medical Advisory Board with The MOG Project that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Journal of The Neurologic Sciences that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial board member with Neuroimmunology Reports that is relevant to AAN interests or activities. Dr. Flanagan has a non-compensated relationship as a Editorial Board Member with Neurology, Neuroimmunology Neuroinflammation (N2) Journal that is relevant to AAN interests or activities.